Dr. Pietrantonio on Survival Rates in Colorectal Cancer

Filippo Pietrantonio, MD
Published: Friday, Jan 13, 2017



Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses survival rates in patients with colorectal cancer (CRC).

The survival of such patients, says Pietrantonio, is generally poor. Typically, clinical trial data show reported survival rates of up to 5 months. However, he explains, there is some heterogeneity in clinical outcomes, as some patients may actually die sooner, while other patients may have longer survivals even if their disease is defined as refractory.

In order to improve these survival rates, Pietrantonio says that identifying the correct patients that are able to receive further treatments is key. This could be accomplished mainly through clinical selection. Currently, most available drugs cannot rely on biomarkers, thus prognostic stratification is, at present, the most important thing to do.



Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses survival rates in patients with colorectal cancer (CRC).

The survival of such patients, says Pietrantonio, is generally poor. Typically, clinical trial data show reported survival rates of up to 5 months. However, he explains, there is some heterogeneity in clinical outcomes, as some patients may actually die sooner, while other patients may have longer survivals even if their disease is defined as refractory.

In order to improve these survival rates, Pietrantonio says that identifying the correct patients that are able to receive further treatments is key. This could be accomplished mainly through clinical selection. Currently, most available drugs cannot rely on biomarkers, thus prognostic stratification is, at present, the most important thing to do.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x